Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 46 of 184 for:    pertuzumab

A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (ATTILA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03811418
Recruitment Status : Withdrawn (Study approved with treatment regimen based on current guidelines. However, reimbursement of IMP was not feasible.)
First Posted : January 22, 2019
Last Update Posted : November 26, 2019
Sponsor:
Collaborators:
Arbeitsgemeinschaft fur Internistische Onkologie
Amgen
Information provided by (Responsible Party):
iOMEDICO AG

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : April 2019
Publications: